Monoclonal Antibody Composition for Quantitative Aβ42 Oligomer Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to provide a specific and quantitative detection of Aβ42 oligomers in human body fluids, which are key early pathogenic factors for Alzheimer's disease, hindering early diagnosis and treatment.
Innovation Solution
Development of a monoclonal antibody composition comprising AB7G and AB11A2 antibodies, specifically designed to bind to Aβ42 monomers and aggregates, with defined amino acid and nucleic acid sequences, enabling a kit for quantitative detection in human body fluids.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional Aβ42 detection kits are used, then general Aβ42 detection is possible, but specific and quantitative detection of Aβ42 oligomers cannot be achieved
Solution Approach 1:
The patent segments the Aβ42 detection into distinct functional components: a capture antibody (AB7G) that specifically binds to Aβ42 oligomers, and a detection antibody (AB11A2) that quantifies the bound oligomers. This segmentation allows the system to differentiate between monomeric and oligomeric forms of Aβ42, achieving both specificity and quantitative measurement capability that conventional kits lack.
Solution Approach 2:
The patent introduces a labeled detection antibody (AB11A2) as an intermediary that bridges the capture antibody-bound oligomer and the detection signal. This intermediary component enables quantitative measurement by providing a measurable signal proportional to the amount of bound Aβ42 oligomer, thereby achieving both specific detection and quantification simultaneously.
2Measurement precision
If high sensitivity detection is achieved, then early diagnosis capability is improved, but detection limit and specificity requirements become more stringent
Solution Approach 1:
The patent optimizes detection parameters including the concentration and affinity of the capture and detection antibodies, the incubation conditions, and the signal detection thresholds. By carefully adjusting these parameters, the system achieves a detection limit of 7.8 pg/mL while maintaining high specificity for Aβ42 oligomers, making early diagnosis feasible without excessive measurement difficulty.
3Measurement precision
If quantitative detection of Aβ42 oligomers is implemented, then early diagnosis accuracy is improved, but sample volume requirements increase
Solution Approach 1:
The patent employs a highly efficient antibody-based detection system that uses minimal amounts of sample material. The capture and detection antibodies work together to amplify the signal from small quantities of Aβ42 oligomers, enabling accurate quantitative detection with minimal sample volumes required for early diagnosis.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The kit achieves high sensitivity and specificity in detecting Aβ42 oligomers, with a detection limit of 7.8 pg/mL, facilitating early diagnosis of Alzheimer's disease using minimal sample volumes.
Implementation Method 1
a monoclonal antibody AB7G, or a fragment thereof, against human Aβ42... the monoclonal antibody AB7G or the fragment thereof is able to specifically bind to an Aβ42 monomer and an Aβ42 aggregate
Implementation Method 2
a monoclonal antibody AB11A2 or a fragment thereof for detecting an Aβ42 monomer or an aggregate thereof
Data Source
AI summary
A monoclonal antibody composition comprises a capture antibody AB7G and a detection antibody AB11A2 for using in preparation of a kit for quantitative detection of amyloid in human body fluids, and the antibodies are monoclonal antibodies secreted by cultured hybridoma cells. The kit specifically recognizes an Aβ42 oligomer, with a linear detection range of 3.9-125 pg/mL, and a lowest detection limit of 7.8 pg/mL. A core technique for kit assembly lies in that the monoclonal antibody AB7G is fixed on a microplate to serve as the capture antibody, and the monoclonal antibody AB11A2 is labeled and then diluted at 1:2000 to serve as the detection antibody. Meanwhile, the present invention relates to heavy and light chain variable region genes of the monoclonal antibodies AB7G and AB11A2 and peptides encoded thereby.